Unknown cell-surface antigen on acute myeloid leukemia cells

The term 'Unknown cell-surface antigen on acute myeloid leukemia cells' is a placeholder designation used in clinical trial registries, patent applications, and drug databases when the specific molecular identity of a therapeutic target has not been publicly disclosed. This typically occurs during the early stages of development for monoclonal antibodies, antibody-drug conjugates (ADCs), or chimeric antigen receptor (CAR) T-cell therapies where the sponsor maintains the target's identity as proprietary information (NCI Drug Dictionary, 2024). While the term does not refer to a single biological entity, it frequently serves as a temporary label for antigens that are later revealed to be well-known AML markers such as CD33, CD123 (IL3RA), or CLEC12A (CLL-1). Historically, the M195 antibody was described as targeting an 'unknown' AML antigen in early clinical reports before its specificity for CD33 was formally confirmed (Tanimoto et al., 1989). Consequently, this entry is considered non-specific and does not represent a unique, validated therapeutic target in a biological sense.

Other names

Undisclosed AML antigenAML-specific surface antigen (unspecified)Acute myeloid leukemia cell surface antigen

Varies depending on the specific therapeutic agent (e.g., antibody-dependent cellular cytotoxicity, inhibition of signaling, or delivery of cytotoxic payload).